News Call for inquiry into NHS contaminated blood scandal Former health secretary says scandal was "criminal" cover-up.
News AbbVie takes aim at Gilead and BMS with 8-week hep C treatme... Trial backs patient-friendly regime in tough to treat strain.
News Can Gilead find another Pharmasset in 2017? Company needs to make acquisition to grow, admits CEO.
Views & Analysis Novartis muscles into NASH fatty liver disease Company's Eric Hughes on what it takes to be leader in NASH - and what can be learnt from hepatitis C.
News New Gilead and AbbVie hepatitis C combos filed in EU Companies aim to cut treatment time and side effects.
Views & Analysis The future of healthcare: the patient advocate and investor ... Examining the views of different stakeholders in the ecosystem supporting drug R&D.
News Taiho's late-stage Duchenne candidate fails trial Taiho has suffered a blow to its near-term pipeline after a drug candidate for Duchenne muscular dystrophy (DMD) missed the mark in a phase 3 trial.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face